Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2018 | SYNTAXES: 10 Year Follow Up is ‘Trendy’

The SYNTAX trial had a 5-year follow-up, but the SYNTAXES (“ES” for extended survival) was specifically designed to find out comparative mortality of both treatments (PCI or surgery) at 10 years in patients with three vessel and/or left main lesions.

TCT 2018 | SYNTAXES: el seguimiento a 10 años se puso de modaThis study retrospectively compared survival data at long term of 897 patients randomized to surgery and 907 patients randomized to PCI from the original SYNTAX.

 

Mortality at 5 years had been 13.9% for PCI vs 11.9% for surgery (CABG) (p=0.1); the difference in favor of surgery was in the combined events rate (37.3% vs 26.9%; p<0.001).

 

Data at 10 years on mortality rendered parallel curves, following the prior 5-year trend (29.4% vs 25.6%; p<0.1). That is when looking at the general population, but when assessing only patients admitted for three vessel disease, we observed a trend in favor of surgery (29,2% vs 21,9%, p=0,07). This trend could not be documented in other subgroups of patients such as diabetics or patients with left main disease.


Read also: TCT 2018 | PREPARE-CALC: Rotational Atherectomy vs. Cutting Balloon in Calcified Lesions.


These outcomes can be considered exploratory since only 72% of the general populations could be followed up to 10 years.

 

Original title: 10- Year Survival after Bypass Surgery versus Drug-Eluting Stents: Preliminary Results of the Randomized SYNTAX Extended Survival study – “SYNTAXES”.

Presenter: Daniel J.F.M. Thuijs.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...